Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients
NCT ID: NCT00257309
Last Updated: 2017-01-19
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE4
Total Enrollment
266 participants
Study Classification
INTERVENTIONAL
Study Start Date
2005-04-30
Study Completion Date
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
General objective: To compare the efficacy and safety of primary angioplasty(PA) with that of thrombolytic therapy (TT) for the treatment of AMI in patients \>=75 years old with ST-segment elevation or LBBB AMI \<6 hours of evolution without contraindications for TT.
Hypothesis: The therapeutical strategy based on PA is superior to that based initially on TT in patients \>=75 years old with AMI.
Participating Centers: 27 Spanish hospitals performing \>50 PA/year. Primary Endpoint (PE): Incidence of the aggregate of death of any cause, reinfarction or disabling stroke at 30 days. There are also 7 secondary endpoints (SE).
Procedure: Diagnosis of inclusion/exclusion criteria --\> Centralized randomization --\> Treatment allocation to 1) TT with weight adjusted TNK + unfractionated heparin or 2) PA within 120 minutes. Estimated Sample size and recruitment time: 570 patients in 19 months. Follow-up: Blinded evaluation of events (PROBE regulations) specified in PE and SE at 30 days and 12 months. Quality control: 100% variable and follow-up review by external CRO. Safety Committee and Event Adjudication Committee formed by experts not participating in the study.
Hypothesis: The therapeutical strategy based on PA is superior to that based initially on TT in patients \>=75 years old with AMI.
Participating Centers: 27 Spanish hospitals performing \>50 PA/year. Primary Endpoint (PE): Incidence of the aggregate of death of any cause, reinfarction or disabling stroke at 30 days. There are also 7 secondary endpoints (SE).
Procedure: Diagnosis of inclusion/exclusion criteria --\> Centralized randomization --\> Treatment allocation to 1) TT with weight adjusted TNK + unfractionated heparin or 2) PA within 120 minutes. Estimated Sample size and recruitment time: 570 patients in 19 months. Follow-up: Blinded evaluation of events (PROBE regulations) specified in PE and SE at 30 days and 12 months. Quality control: 100% variable and follow-up review by external CRO. Safety Committee and Event Adjudication Committee formed by experts not participating in the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
NCT06769256
ST-segment Elevation Myocardial Infarction (STEMI)
RECRUITING
PHASE4
Senior PAMI: Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly
NCT00136929
Myocardial Infarction
UNKNOWN
NA
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
NCT00623623
Myocardial Infarction
COMPLETED
PHASE3
STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction
NCT02777580
Myocardial Infarction
COMPLETED
PHASE4
Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial
NCT00157261
Heart Arrest
TERMINATED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis of the study. In patients of 75 or more years of age with AMI and ST-elevation or LBBB, the treatment strategy based on primary angioplasty is superior to the treatment strategy based on initial fibrinolytic therapy for reducing the incidence of death, re-infarction and disabling CVA at 30 days. This benefit is maintained at 12 months.
Objectives General objective of the study. To compare the efficacy and safety of primary angioplasty and fibrinolytic treatment in \>=75 year-old patients with AMI eligible for fibrinolytic therapy in Spanish medical centers with an active program of primary angioplasty.
Primary end point: Incidence of the combined end point of all-cause death, re-infartion or disabling stroke at 30 days
Secondary end points:
* All-cause death at 30 days
* Incidence of the combined end point of all-cause death, disabling CVA or de novo heart failure at 30 days
* Incidence of recurrent ischemia requiring emergency catheterization in the first 30 days
* Cause of death at 30 days classified in three groups:
1. Shock or heart (pump) failure
2. Mechanical complications (ruptures) or electromechanical dissociation
3. Other causes (including bleeding)
* Incidence of major bleeding during hospital admission
* All-cause mortality at 12 months
* Period of time elapsed until presentation of any of the composite of all-cause death, reinfarction or disabling CVA at 12 months
* Period of time elapsed until the presentation of any composite of all-cause death, reinfarction, disabling CVA or non-elective hospital readmission for cardiac causes (unstable angina, heart failure, non-elective coronary revascularization at 12 months.
TYPE AND DESIGN OF THE CLINICAL TRIAL Clinical trial status Phase IV trial Description of randomization process The treatment strategy will be determined by a centralized randomization process, using a telephone system. Eligible patients will be randomized to one of two (2) treatment arms: fibrinolytic treatment or primary angioplasty.
Control and design This is a randomized multicenter, open blind clinical trial designed to compare the efficacy and safety of primary angioplasty vs. thrombolytic treatment in \>=75 year-old patients with AMI and ST-elevation or de novo LBBB, eligible for thrombolysis, admitted at Spanish medical centers that have an active primary angioplasty program, within the first 6 hours after symptom onset.
Masking techniques Being an open trial there are not masking techniques, nor will there be an emergency opening procedure of emergency codes.
Pre-inclusion / clearance period Not applicable
SUBJECT SELECTION Inclusion / exclusion criteria Subjects must be \>=75 years of age with AMI and ST-elevation or de novo LBBB, eligible for thrombolytic therapy, admitted in any Spanish medical center in which there is an active primary angioplasty program within the first 6 hours after symptom onset.
Each patient must fulfill all inclusion criteria and none of the exclusion criteria.
Inclusion criteria:
1. Subjects of 75 or more years of age
2. Diagnosis of AMI: chest pain or any symptom of myocardial ischemia of, at least, 20 minutes of duration, not responding to nitrate therapy, an evolution period of less than 6 hours after symptom onset until randomization process, and, at least, one of the following alterations:
1. ST-elevation \>=2 mm in 2 or more precordial leads
2. ST-elevation \>=1 mm in 2 or more anterior leads
3. Complete de novo (or probably de novo) left bundle branch block (LBBB)
3. Subject should be able to give informed consent prior to randomization process and should agree to fulfill all procedures described in the protocol, including follow-up after hospital discharge. A written consent signed by a close relative with witness is also acceptable.
Exclusion criteria:
1. Documented contraindication to the use of fibrinolytics. 1.1. Internal active bleeding or known history of hemorrhagic diathesis 1.2. History of previous CVA of any kind or at any time 1.3. Intracranial tumor, arteriovenous malformation, aneurysm or cerebral aneurysm repair 1.4. Major surgery, parenchymal biopsy, ocular surgery or severe traumatism in the 6 weeks prior to randomization 1.5. Unexplained puncture in a non-compressible vascular location in the last 24 hours prior to randomization 1.6. Confirmed arterial hypertension with a reliable measurement of systolic AP \>180 mmHg or diastolic AP \>110 mmHg 1.7. Known thrombocytopenia \< 100.000 platelets/mL 1.8. Prolonged (\>20 minutes) or traumatic cardiopulmonar resuscitation (CPR) in the 2 weeks prior to randomization 1.9. History or signs suggesting aortic dissection
2. Cardiogenic shock
3. Estimated door-to-needle time \>120 minutes
4. Administration of fibrinolysis in the 14 days prior to randomization
5. Administration of any glycoprotein IIa/IIIb inhibitor in the 24 hours prior to randomization
6. Administration of any Low Molecular Weight Heparin (LMWH) in the 8 hours prior to randomization
7. Actual oral anticoagulant treatment
8. Suspected AMI secondary to occlusion of one lesion treated previously with a percutaneous coronary intervention (within the previous 30 days for angioplasty or conventional stent and within the previous 12 months for coated stents)
9. Dementia or acute confusional state at the time of randomization
10. Subject incapacity or unwillingness to give informed consent -at least, verbally
11. Known renal failure (basal creatinine\> 2,5 mg/dl)
12. Reduced life expectancy (\<12 months) due to advanced or terminal concomitant condition
13. Subject participation in another clinical trial (assessing a drug or a device) in the 30 days prior to randomization
Diagnostic criteria for the pathologies of the study
Patients with a diagnosis of AMI presenting with:
* Chest pain or any symptom of myocardial ischemia of, at least, 20 minutes of duration, not responding to nitrate therapy and an evolution period of less than 6 hours after symptom onset until randomization process, with, at least, one of the following alterations:
* ST-elevation \>=2 mm in 2 or more precordial leads
* ST-elevation \>=1 mm in 2 or more anterior leads
* Complete de novo (or probably de novo) left bundle branch block (LBBB)
Estimate of sample size For the following conditions: α = 0.05 (2 tailed), power: 80% (β = 0.20) and assuming a composite event incidence rate (death, reinfarction and disabling CVA) based on previous registries (21.7% in the fibrinolysis group and 12.8% in the PA group), a sample size of 282 patients per group is needed to demonstrate that difference (8.9% in absolute terms and 40% in relative terms). Assuming a loss to follow-up rate of 1%, the total number is 570 patients
Estimated loss of patients prior to randomization During a period of 3 months all patients meeting inclusion criteria who, for any reason, are not enrolled in the study will be included in a registry with an abbreviated CRF recording inclusion/exclusion criteria, the reason for non-enrollment and follow-up at 30 days and 12 months.
Objectives General objective of the study. To compare the efficacy and safety of primary angioplasty and fibrinolytic treatment in \>=75 year-old patients with AMI eligible for fibrinolytic therapy in Spanish medical centers with an active program of primary angioplasty.
Primary end point: Incidence of the combined end point of all-cause death, re-infartion or disabling stroke at 30 days
Secondary end points:
* All-cause death at 30 days
* Incidence of the combined end point of all-cause death, disabling CVA or de novo heart failure at 30 days
* Incidence of recurrent ischemia requiring emergency catheterization in the first 30 days
* Cause of death at 30 days classified in three groups:
1. Shock or heart (pump) failure
2. Mechanical complications (ruptures) or electromechanical dissociation
3. Other causes (including bleeding)
* Incidence of major bleeding during hospital admission
* All-cause mortality at 12 months
* Period of time elapsed until presentation of any of the composite of all-cause death, reinfarction or disabling CVA at 12 months
* Period of time elapsed until the presentation of any composite of all-cause death, reinfarction, disabling CVA or non-elective hospital readmission for cardiac causes (unstable angina, heart failure, non-elective coronary revascularization at 12 months.
TYPE AND DESIGN OF THE CLINICAL TRIAL Clinical trial status Phase IV trial Description of randomization process The treatment strategy will be determined by a centralized randomization process, using a telephone system. Eligible patients will be randomized to one of two (2) treatment arms: fibrinolytic treatment or primary angioplasty.
Control and design This is a randomized multicenter, open blind clinical trial designed to compare the efficacy and safety of primary angioplasty vs. thrombolytic treatment in \>=75 year-old patients with AMI and ST-elevation or de novo LBBB, eligible for thrombolysis, admitted at Spanish medical centers that have an active primary angioplasty program, within the first 6 hours after symptom onset.
Masking techniques Being an open trial there are not masking techniques, nor will there be an emergency opening procedure of emergency codes.
Pre-inclusion / clearance period Not applicable
SUBJECT SELECTION Inclusion / exclusion criteria Subjects must be \>=75 years of age with AMI and ST-elevation or de novo LBBB, eligible for thrombolytic therapy, admitted in any Spanish medical center in which there is an active primary angioplasty program within the first 6 hours after symptom onset.
Each patient must fulfill all inclusion criteria and none of the exclusion criteria.
Inclusion criteria:
1. Subjects of 75 or more years of age
2. Diagnosis of AMI: chest pain or any symptom of myocardial ischemia of, at least, 20 minutes of duration, not responding to nitrate therapy, an evolution period of less than 6 hours after symptom onset until randomization process, and, at least, one of the following alterations:
1. ST-elevation \>=2 mm in 2 or more precordial leads
2. ST-elevation \>=1 mm in 2 or more anterior leads
3. Complete de novo (or probably de novo) left bundle branch block (LBBB)
3. Subject should be able to give informed consent prior to randomization process and should agree to fulfill all procedures described in the protocol, including follow-up after hospital discharge. A written consent signed by a close relative with witness is also acceptable.
Exclusion criteria:
1. Documented contraindication to the use of fibrinolytics. 1.1. Internal active bleeding or known history of hemorrhagic diathesis 1.2. History of previous CVA of any kind or at any time 1.3. Intracranial tumor, arteriovenous malformation, aneurysm or cerebral aneurysm repair 1.4. Major surgery, parenchymal biopsy, ocular surgery or severe traumatism in the 6 weeks prior to randomization 1.5. Unexplained puncture in a non-compressible vascular location in the last 24 hours prior to randomization 1.6. Confirmed arterial hypertension with a reliable measurement of systolic AP \>180 mmHg or diastolic AP \>110 mmHg 1.7. Known thrombocytopenia \< 100.000 platelets/mL 1.8. Prolonged (\>20 minutes) or traumatic cardiopulmonar resuscitation (CPR) in the 2 weeks prior to randomization 1.9. History or signs suggesting aortic dissection
2. Cardiogenic shock
3. Estimated door-to-needle time \>120 minutes
4. Administration of fibrinolysis in the 14 days prior to randomization
5. Administration of any glycoprotein IIa/IIIb inhibitor in the 24 hours prior to randomization
6. Administration of any Low Molecular Weight Heparin (LMWH) in the 8 hours prior to randomization
7. Actual oral anticoagulant treatment
8. Suspected AMI secondary to occlusion of one lesion treated previously with a percutaneous coronary intervention (within the previous 30 days for angioplasty or conventional stent and within the previous 12 months for coated stents)
9. Dementia or acute confusional state at the time of randomization
10. Subject incapacity or unwillingness to give informed consent -at least, verbally
11. Known renal failure (basal creatinine\> 2,5 mg/dl)
12. Reduced life expectancy (\<12 months) due to advanced or terminal concomitant condition
13. Subject participation in another clinical trial (assessing a drug or a device) in the 30 days prior to randomization
Diagnostic criteria for the pathologies of the study
Patients with a diagnosis of AMI presenting with:
* Chest pain or any symptom of myocardial ischemia of, at least, 20 minutes of duration, not responding to nitrate therapy and an evolution period of less than 6 hours after symptom onset until randomization process, with, at least, one of the following alterations:
* ST-elevation \>=2 mm in 2 or more precordial leads
* ST-elevation \>=1 mm in 2 or more anterior leads
* Complete de novo (or probably de novo) left bundle branch block (LBBB)
Estimate of sample size For the following conditions: α = 0.05 (2 tailed), power: 80% (β = 0.20) and assuming a composite event incidence rate (death, reinfarction and disabling CVA) based on previous registries (21.7% in the fibrinolysis group and 12.8% in the PA group), a sample size of 282 patients per group is needed to demonstrate that difference (8.9% in absolute terms and 40% in relative terms). Assuming a loss to follow-up rate of 1%, the total number is 570 patients
Estimated loss of patients prior to randomization During a period of 3 months all patients meeting inclusion criteria who, for any reason, are not enrolled in the study will be included in a registry with an abbreviated CRF recording inclusion/exclusion criteria, the reason for non-enrollment and follow-up at 30 days and 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acute Myocardial Infarction
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Thrombolysis
Weight adjusted tenecteplase bolus + Unfrationated heparin
Group Type
ACTIVE_COMPARATOR
Tenecteplase + UFH (+ clopidogrel, since 01/97)
Intervention Type
DRUG
Primary angioplasty
Primary angioplasty
Group Type
ACTIVE_COMPARATOR
Primary angioplasty
Intervention Type
PROCEDURE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tenecteplase + UFH (+ clopidogrel, since 01/97)
Intervention Type
DRUG
Primary angioplasty
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects of 75 or more years of age
2. Diagnosis of AMI: chest pain or any symptom of myocardial ischemia of, at least, 20 minutes of duration, not responding to nitrate therapy, an evolution period of less than 6 hours after symptom onset until randomization process, and, at least, one of the following alterations:
1. ST-elevation \>=2 mm in 2 or more precordial leads
2. ST-elevation \>=1 mm in 2 or more anterior leads
3. Complete de novo (or probably de novo) left bundle branch block (LBBB)
3. Subject should be able to give informed consent prior to randomization process and should agree to fulfill all procedures described in the protocol, including follow-up after hospital discharge. A written consent signed by a close relative with witness is also acceptable.
2. Diagnosis of AMI: chest pain or any symptom of myocardial ischemia of, at least, 20 minutes of duration, not responding to nitrate therapy, an evolution period of less than 6 hours after symptom onset until randomization process, and, at least, one of the following alterations:
1. ST-elevation \>=2 mm in 2 or more precordial leads
2. ST-elevation \>=1 mm in 2 or more anterior leads
3. Complete de novo (or probably de novo) left bundle branch block (LBBB)
3. Subject should be able to give informed consent prior to randomization process and should agree to fulfill all procedures described in the protocol, including follow-up after hospital discharge. A written consent signed by a close relative with witness is also acceptable.
Exclusion Criteria
1. Documented contraindication to the use of fibrinolytics. 1.1. Internal active bleeding or known history of hemorrhagic diathesis 1.2. History of previous CVA of any kind or at any time 1.3. Intracranial tumor, arteriovenous malformation, aneurysm or cerebral aneurysm repair 1.4. Major surgery, parenchymal biopsy, ocular surgery or severe traumatism in the 6 weeks prior to randomization 1.5. Unexplained puncture in a non-compressible vascular location in the last 24 hours prior to randomization 1.6. Confirmed arterial hypertension with a reliable measurement of systolic AP \>180 mmHg or diastolic AP \>110 mmHg 1.7. Known thrombocytopenia \< 100.000 platelets/mL 1.8. Prolonged (\>20 minutes) or traumatic cardiopulmonar resuscitation (CPR) in the 2 weeks prior to randomization 1.9. History or signs suggesting aortic dissection
2. Cardiogenic shock
3. Estimated door-to-needle time \>120 minutes
4. Administration of fibrinolysis in the 14 days prior to randomization
5. Administration of any glycoprotein IIa/IIIb inhibitor in the 24 hours prior to randomization
6. Administration of any Low Molecular Weight Heparin (LMWH) in the 8 hours prior to randomization
7. Actual oral anticoagulant treatment
8. Suspected AMI secondary to occlusion of one lesion treated previously with a percutaneous coronary intervention (within the previous 30 days for angioplasty or conventional stent and within the previous 12 months for coated stents)
9. Dementia or acute confusional state at the time of randomization
10. Subject incapacity or unwillingness to give informed consent -at least, verbally
11. Known renal failure (basal creatinine\> 2,5 mg/dl)
12. Reduced life expectancy (\<12 months) due to advanced or terminal concomitant condition
13. Subject participation in another clinical trial (assessing a drug or a device) in the 30 days prior to randomization
2. Cardiogenic shock
3. Estimated door-to-needle time \>120 minutes
4. Administration of fibrinolysis in the 14 days prior to randomization
5. Administration of any glycoprotein IIa/IIIb inhibitor in the 24 hours prior to randomization
6. Administration of any Low Molecular Weight Heparin (LMWH) in the 8 hours prior to randomization
7. Actual oral anticoagulant treatment
8. Suspected AMI secondary to occlusion of one lesion treated previously with a percutaneous coronary intervention (within the previous 30 days for angioplasty or conventional stent and within the previous 12 months for coated stents)
9. Dementia or acute confusional state at the time of randomization
10. Subject incapacity or unwillingness to give informed consent -at least, verbally
11. Known renal failure (basal creatinine\> 2,5 mg/dl)
12. Reduced life expectancy (\<12 months) due to advanced or terminal concomitant condition
13. Subject participation in another clinical trial (assessing a drug or a device) in the 30 days prior to randomization
Minimum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondo de Investigacion Sanitaria
OTHER
Sponsor Role
collaborator
Sanofi
INDUSTRY
Sponsor Role
collaborator
Cordis Corporation
INDUSTRY
Sponsor Role
collaborator
Medtronic
INDUSTRY
Sponsor Role
collaborator
Guidant Corporation
INDUSTRY
Sponsor Role
collaborator
Boston Scientific Corporation
INDUSTRY
Sponsor Role
collaborator
Spanish Society of Cardiology
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Héctor Bueno
(Past) President. WG on IHD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hector Bueno, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Spanish Society of Cardiology (WG on Ischemic Heart Disease and CCUs)
Rosa Ana Hernández-Antolín, MD
Role: PRINCIPAL_INVESTIGATOR
Spanish Society of Cardiology (WG on Interventional Cardiology)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Son Dureta
Palma de Mallorca, Balearic Islands, Spain
Site Status
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Site Status
Hospital Clinic i Provincial de Barcelona
Barcelona, Barcelona, Spain
Site Status
Hospital Universitario de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Site Status
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Site Status
Hospital Universitario Virgen de las Nieves
Granada, Granada, Spain
Site Status
Hospital Juan Ramón Jiménez
Huelva, Huelva, Spain
Site Status
Complejo Hospitalario Universitario "Juan Canalejo"
A Coruña, La Coruña, Spain
Site Status
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, La Coruña, Spain
Site Status
Complejo Hospitalario de León
León, León, Spain
Site Status
Hospital General Universitario "Gregorio Maranon"
Madrid, Madrid, Spain
Site Status
Hospital Clínico "San Carlos"
Madrid, Madrid, Spain
Site Status
Hospital 12 de Octubre
Madrid, Madrid, Spain
Site Status
Hospital Universitario La Paz
Madrid, Madrid, Spain
Site Status
Hospital Universitario "Virgen de la Victoria"
Málaga, Málaga, Spain
Site Status
Hospital de Navarra
Pamplona, Navarre, Spain
Site Status
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Site Status
Hospital Universitario Virgen Macarena
Seville, Sevilla, Spain
Site Status
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Site Status
Complejo Hospitalario de Toledo Hospital Virgen de la Salud
Toledo, Toledo, Spain
Site Status
Consorcio Hospital General Universitario de Valencia
Valencia, Valencia, Spain
Site Status
Hospital Clínico Universitario de Valladolid
Valladolid, Valladolid, Spain
Site Status
Hospital de Cruces
Barakaldo, Vizcaya, Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Bardaji A, Bueno H, Fernandez-Ortiz A, Cequier A, Auge JM, Heras M. [Type of treatment and short-term outcome in elderly patients with acute myocardial infarction admitted to hospitals with a primary coronary angioplasty facility. The TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) Registry]. Rev Esp Cardiol. 2005 Apr;58(4):351-8. Spanish.
Reference Type
BACKGROUND
Cequier A, Bueno H, Auge JM, Bardaji A, Fernandez-Ortiz A, Heras M. [Characteristics and mortality following primary percutaneous coronary intervention for acute myocardial infarction in Spain. Results from the TRIANA 1 (TRatamiento del Infarto Agudo de miocardio eN Ancianos) Registry]. Rev Esp Cardiol. 2005 Apr;58(4):341-50. Spanish.
Reference Type
BACKGROUND
Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, Garcia EJ, Lopez-Sendon JL, Macaya C, Hernandez-Antolin R; TRIANA Investigators. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011 Jan;32(1):51-60. doi: 10.1093/eurheartj/ehq375. Epub 2010 Oct 22.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIS PI042122
Identifier Type: -
Identifier Source: secondary_id
EUDRACT 2004-001943-31
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
NCT01347580
COMPLETED
PHASE4
Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)
NCT03504202
UNKNOWN
NA
Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients
NCT01109134
COMPLETED
PHASE3
Thrombolysis in Myocardial Infarction (TIMI)
NCT00000505
COMPLETED
PHASE3
Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty
NCT02592694
UNKNOWN
PHASE4
Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI
NCT03435133
COMPLETED
NA
Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation
NCT00445263
TERMINATED
PHASE4
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
NCT07298044
NOT_YET_RECRUITING
PHASE4
A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)
NCT02182011
COMPLETED
PHASE3
Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)
NCT05210465
COMPLETED
Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study
NCT06736353
COMPLETED
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
NCT03998319
RECRUITING
PHASE3
Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19
NCT04760821
UNKNOWN
PHASE2
Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention
NCT01738100
UNKNOWN
PHASE2
Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty
NCT00306228
COMPLETED
PHASE4
ThromboAblation in Acute Myocardial Infarction
NCT00650975
TERMINATED
PHASE2/PHASE3
A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks
NCT00604695
COMPLETED
PHASE2
Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
NCT02131220
COMPLETED
PHASE4
Myocardial Protection With Adenosine During Primary Percutaneous Coronary Intervention in Pts With STEMI
NCT00781404
COMPLETED
PHASE3
Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study
NCT01916902
WITHDRAWN
PHASE4
Thrombolysis in Myocardial Ischemia Trial (TIMI III)
NCT00000472
COMPLETED
PHASE3
Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction
NCT01374321
COMPLETED
PHASE2
GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction
NCT00538317
COMPLETED
PHASE4
Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
NCT01181388
UNKNOWN
NA
Adjunctive, Low-dose tPA in Primary PCI for STEMI
NCT03335839
COMPLETED
PHASE3